Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2023 | $3.00 → $1.00 | Buy → Neutral | B. Riley Securities |
| 8/30/2023 | $3.00 | Buy | B. Riley Securities |
| 12/22/2022 | $3.00 | Overweight | Cantor Fitzgerald |
| 12/12/2022 | $3.00 | Overweight | Piper Sandler |
| 12/14/2021 | $21.00 → $11.00 | Buy | HC Wainwright & Co. |
B. Riley Securities downgraded X4 Pharmaceuticals from Buy to Neutral and set a new price target of $1.00 from $3.00 previously
B. Riley Securities resumed coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $3.00
Cantor Fitzgerald initiated coverage of X4 Pharmaceuticals with a rating of Overweight and set a new price target of $3.00